0000899243-20-004179.txt : 20200211 0000899243-20-004179.hdr.sgml : 20200211 20200211212330 ACCESSION NUMBER: 0000899243-20-004179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200211 FILED AS OF DATE: 20200211 DATE AS OF CHANGE: 20200211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MACKAY GEOFFREY CENTRAL INDEX KEY: 0001741849 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38537 FILM NUMBER: 20599533 MAIL ADDRESS: STREET 1: C/O AVROBIO, INC. STREET 2: ONE KENDALL SQ, BLDG. 300, STE. 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVROBIO, Inc. CENTRAL INDEX KEY: 0001681087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 810710585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7819626030 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AvroBio, Inc. DATE OF NAME CHANGE: 20160729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-11 0 0001681087 AVROBIO, Inc. AVRO 0001741849 MACKAY GEOFFREY C/O AVROBIO, INC. 1 KENDALL SQ. BLDG 300, STE 201 CAMBRIDGE MA 02139 1 1 0 0 See Remarks Common Stock 2020-02-11 4 S 0 44596 27.3563 D 364927 D Common Stock 2020-02-11 4 S 0 18404 28.0971 D 346523 D Common Stock 72604 I By son of reporting person Common Stock 72604 I By daughter of reporting person The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.995, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. President and Chief Executive Officer /s/ Steven Avruch, as Attorney-in-Fact 2020-02-11